Strategic Growth SteriMax is a privately held Canadian pharmaceutical manufacturer based in Oakville with recent expansion activity through the acquisition of Andonepharma, signaling a growth trajectory and potential cross-sell opportunities across combined product portfolios, supply chains, and customer networks.

Product Portfolio The company has a history of launching specialty injectable drugs (for example Arsenic Trioxide, Mycophenolate Mofetil, Bupivacaine Hydrochloride, Ethacrynate Sodium), indicating strength in hospital and clinical injectables which can be leveraged to upsell to hospitals, clinics, and distributors seeking ready-to-roll-out sterile formulations.

Market Position With revenue in the mid tens of millions and a modest employee base, SteriMax occupies a niche in the Canadian market that may benefit from targeted partnerships with larger distributors and contract manufacturers to scale access while maintaining agility and specialized customer service.

Customer Target Key engagement opportunities exist with hospital networks, specialty clinics, and provincial procurement programs that commonly source sterile injectables, enabling a focused sales approach for both existing products and newly integrated Andonepha rma lines post-acquisition.

Innovation & Compliance Adopting and marketing TrackWise and other tech stack capabilities alongside regulatory-compliant manufacturing for injectables presents a differentiator for quality-conscious buyers and can be positioned to win tenders requiring robust quality systems and traceability.